Insider Selling Signals at TEMPUS AI
The most recent 10‑K4 filing reveals that director‑dealing owner Epstein David R. sold 370 shares of TEMPUS AI’s Class A common stock on 2026‑11‑02 pursuant to a Rule 10b5‑1 plan, realizing proceeds of $27 552. The transaction price of $74.29 was only $1.32 below the market close of $75.61. Although the size of the sale is modest relative to the company’s $14.3 billion market capitalisation, it follows a pattern of frequent, small‑scale liquidations that has persisted since early 2026.
1. Pattern of Insider Activity
- Epstein’s Trading History – Over the past eight months, Epstein has executed a series of Rule 10b5‑1 sales ranging from 250 to 370 shares per transaction.
- Recent Purchase – In May 2026, he acquired 5 913 shares, after which subsequent 10‑K filings report sales of 250–370 shares each.
- Cumulative Effect – The net result is a gradual erosion of his stake, suggesting a systematic rebalancing rather than a panic‑sell response.
These disciplined, rule‑based transactions are priced near the market close, indicating that Epstein is not attempting to time the market. The adoption of the Rule 10b5‑1 plan in August 2024 further mitigates concerns about insider abuse.
2. Market Context
- Financial Position – TEMPUS AI operates in a competitive health‑tech space, with a negative P/E ratio of –31.05 and a 52‑week high of $89.09.
- Share Price Performance – The company’s share price has grown only +4.9 % over the past year, a modest change that reflects limited upside potential in the near term.
- Insider Sales by Other Executives – Officer Vanessa Kubo has also filed a Rule 144 notice and is liquidating shares, reinforcing the perception of a gradual shift of capital away from the stock.
3. Investor Implications
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026‑11‑02 | Epstein David R. | Sell | 370.00 | 74.29 | Class A Common Stock |
| 2026‑11‑02 | Fukushima Ryan (CEO, Data) | Buy | 100 000.00 | N/A | Class A Common Stock |
| 2026‑11‑02 | Fukushima Ryan (CEO, Data) | Sell | 80.00 | 74.29 | Class A Common Stock |
The insider activity, coupled with a negative P/E ratio, may signal caution for investors. However, the high social‑media buzz (+20 sentiment score) and exceptionally high buzz percentage (97.97 %) suggest that market participants still view TEMPUS AI’s AI‑driven diagnostics platform as a long‑term value driver.
4. Forward Outlook for Healthcare Professionals
For clinicians and researchers who rely on TEMPUS AI’s diagnostic tools, the current insider selling trend does not directly affect product availability or clinical performance. The company continues to invest in AI algorithms that improve diagnostic accuracy for oncology and rare disease conditions. Nonetheless, investors should monitor the company’s earnings reports and subsequent insider filings to assess whether the rebalancing of shares persists or reverses, and whether the platform can translate into stronger cash flows and long‑term shareholder value.
